- ACCESS Pharmaceuticals has signed a letter of intent to acquire Tacora Corp, a privately-held company based in Seattle, USA, which is working on developing bioresponsive smart polymers seeking to mimic the body's own approaches for the regulated delivery of drugs. Under the terms of the agreement, the purchase price is contingent upon the achievement of certain technology milestones. Stock up to a maximum of $14 million could be payable over a 30-month period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze